All deliverables
Print · ABPI Regulated · HCPs

HCP Detail Aid.
Evidence-led. Visually compelling. Built to survive MLR intact.

Audience
HCPs — GPs & specialists
Format
4–16pp A4 PDF
Compliance
ABPI 2024
Price from
£350
What's produced

A multi-page A4 leave-piece built on clinical evidence.

The HCP Detail Aid is a multi-page A4 visual leave-piece designed to support the rep conversation and communicate your product's evidence base at the level a specialist audience demands. It includes MOA summary, clinical trial data, safety profile, prescribing information, and Vancouver-referenced citations.

Aria sources the evidence first, mapping the trial landscape and identifying the strongest data points. Medi writes the clinical copy from primary sources. Chart handles the data visualisation — selecting the right chart format for each endpoint and ensuring statistical accuracy at every step.

Viz designs the full-page A4 layouts, with print-ready output at 300dpi with bleed and safe zones. Reg reviews against ABPI 2024 and generates the MLR reference pack. Complex tiers include Signal's competitive positioning analysis.

The team

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

SY
Sys
Head of Systems
ME
Medi
Medical Writer
RE
Reg
Compliance Reviewer
AR
Aria
Research Analyst
VI
Viz
Visual Director
PA
Pace
Project Manager
CH
Chart
Data Viz Specialist
SI
Signal
Digital Strategist
Complexity tiers

Simple, Medium, or Complex — you choose the depth.

Simple Medium Complex
Scope 4pp summary 8pp + trial data charts 12–16pp full evidence narrative + competitor positioning
Team Sys, Medi, Reg, Aria, Viz, Pace + Chart + Signal
Price range ~£350 ~£680 ~£1,400
Best for Launch product, single key trial Multi-endpoint data, detail-driven specialist audience Established biologic, class comparison, competitive territory
Example output

What it looks like.

Verixtol® — HCP Detail Aid (Simple)
Verixtol® (verixtumab 150mg) — Clinical Summary
Indication
Verixtol (verixtumab 150mg) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
Mechanism of action
Verixtumab is a fully human IgG1 monoclonal antibody that selectively binds to and neutralises interleukin-17A (IL-17A). By blocking IL-17A signalling at the skin level, verixtumab reduces keratinocyte activation and downstream inflammatory cytokine production, leading to resolution of psoriatic plaques.
72%
PASI 90 at week 16, VERIFY-1 (n=312, p<0.0001 vs placebo)1
Prescribing information
Consult SmPC before prescribing. Legal category: POM. Starting dose: 150mg SC at weeks 0, 1, 2, 3, 4 then monthly. MA number: EU/1/25/1847/001–003. Cost: £9,800 per patient per year (list price). Full prescribing information available on request.
1. VERIFY-1. NEJM. 2024;391:2341–2354.
HAR-VER-2026-001 | Date of preparation: March 2026 Spectrum& — spectrumand.com
Verixtol® — HCP Detail Aid (Medium)
Verixtol® — VERIFY-1 Trial Data Summary
Primary endpoint: PASI 90 at week 16
72%
Verixtol 150mg (n=208)
4%
Placebo (n=104)
Odds ratio 72.4 (95% CI 20.8–252.3); p<0.0001. Responder analysis, LOCF imputation.
Secondary endpoints
IGA 0/1 (clear/almost clear): 78% vs 5% (p<0.0001). PASI 75: 89% vs 7% (p<0.0001). DLQI 0/1: 68% vs 11% (p<0.0001). Time to PASI 50: median 4.2 weeks (verixtol) vs 14.7 weeks (placebo).
Safety profile — VERIFY-1 (52-week data)
Most common adverse events (≥5%): nasopharyngitis (14% vs 11%), upper respiratory tract infection (9% vs 8%), injection site reactions (6% vs 3%). Serious adverse events: 3% verixtol vs 4% placebo. No cases of inflammatory bowel disease observed in the psoriasis population.
HAR-VER-2026-001 | Date of preparation: March 2026 Spectrum& — spectrumand.com
Verixtol® — HCP Detail Aid (Complex)
Verixtol® — Full Evidence Narrative & Comparative Positioning
Evidence base: VERIFY programme (n=1,847)
The VERIFY clinical programme comprises four Phase III randomised controlled trials evaluating verixtumab 150mg and 300mg across two indications (plaque psoriasis and axial spondyloarthritis), representing 1,847 patients with up to 3 years of follow-up data.
Comparative analysis: IL-17A class
Indirect treatment comparison (ITC) data from a network meta-analysis of 34 RCTs (n=18,412) demonstrates that verixtumab 150mg achieves numerically superior PASI 90 response rates at week 16 versus secukinumab 300mg (72% vs 61%) and ixekizumab 80mg Q4W (72% vs 68%), though these comparisons were not powered for formal superiority testing.4
Important: Indirect comparisons should be interpreted with caution. No head-to-head trials exist. Data from Bard et al, J Eur Acad Dermatol 2025.4
4. Bard K et al. Network meta-analysis of IL-17A inhibitors in plaque psoriasis. J Eur Acad Dermatol Venereol. 2025;39(2):341-355.
HAR-VER-2026-001 | Date of preparation: March 2026 Spectrum& — spectrumand.com

Full rendered examples will be available at launch.

ABPI 2024 Compliance

This deliverable is subject to the ABPI 2024 Code of Practice. All materials include a full Reg compliance review, MLR reference pack, and mandatory statement audit before delivery.

Start your HCP Detail Aid.

Tell us about your brief. We'll assemble the right team and get started today.

Start a project →